{"nctId":"NCT02023879","briefTitle":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","startDateStruct":{"date":"2013-12-16"},"conditions":["Hypercholesterolemia"],"count":233,"armGroups":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Alirocumab","Drug: Placebo (for Alirocumab)","Drug: Non-statin LMT","Other: Diet Alone"]},{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)","type":"OTHER","interventionNames":["Drug: Alirocumab","Drug: Non-statin LMT","Other: Diet Alone"]},{"label":"Alirocumab 150 mg Q4W/Up to 150 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Placebo (for Alirocumab)","Drug: Non-statin LMT","Other: Diet Alone"]}],"interventions":[{"name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent®"]},{"name":"Placebo (for Alirocumab)","otherNames":[]},{"name":"Non-statin LMT","otherNames":[]},{"name":"Diet Alone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nParticipants with primary hypercholesterolemia (heterozygous familial hypercholesterolemia \\[heFH\\] or non-FH) not adequately controlled with their non-statin LMT (either ezetimibe or fenofibrate) or diet alone.\n\nExclusion criteria:\n\n* LDL-C \\<70 mg/dL (1.81 mmol/L) at screening for statin intolerant participants at very high cardiovascular (CV) risk;\n* LDL-C \\<100 mg/dL (\\<2.59 mmol/L) at screening for statin intolerant participants at high or moderate CV risk or, participants not fulfilling the statin intolerant definition at moderate CV risk;\n* LDL-C ≥160 mg/dL (≥4.1 mmol/L) at screening for participants receiving diet only or, participants not fulfilling the statin intolerant definition at moderate CV risk and receiving a non-statin LMT.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)","description":"Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.3"},{"groupId":"OG001","value":"-53.5","spread":"1.6"},{"groupId":"OG002","value":"-51.7","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"2.1"},{"groupId":"OG001","value":"-55.3","spread":"1.5"},{"groupId":"OG002","value":"-54.6","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.5"},{"groupId":"OG001","value":"-50.8","spread":"1.7"},{"groupId":"OG002","value":"-41.7","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"2.3"},{"groupId":"OG001","value":"-51.5","spread":"1.6"},{"groupId":"OG002","value":"-44.8","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.0"},{"groupId":"OG001","value":"-53.6","spread":"1.4"},{"groupId":"OG002","value":"-52.3","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.9"},{"groupId":"OG001","value":"-54.1","spread":"1.3"},{"groupId":"OG002","value":"-55.0","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"2.1"},{"groupId":"OG001","value":"-39.7","spread":"1.5"},{"groupId":"OG002","value":"-38.9","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"2.0"},{"groupId":"OG001","value":"-41.2","spread":"1.4"},{"groupId":"OG002","value":"-40.9","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"2.1"},{"groupId":"OG001","value":"-45.3","spread":"1.5"},{"groupId":"OG002","value":"-44.2","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"1.9"},{"groupId":"OG001","value":"-46.9","spread":"1.3"},{"groupId":"OG002","value":"-46.7","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"1.6"},{"groupId":"OG001","value":"-34.0","spread":"1.1"},{"groupId":"OG002","value":"-32.3","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"2.2"},{"groupId":"OG001","value":"-38.4","spread":"1.6"},{"groupId":"OG002","value":"-31.3","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.2"},{"groupId":"OG001","value":"-43.4","spread":"1.5"},{"groupId":"OG002","value":"-34.9","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.6"},{"groupId":"OG001","value":"-32.6","spread":"1.2"},{"groupId":"OG002","value":"-24.5","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis","description":"Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and \\<5%.\n\nHigh CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia.\n\nVery high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion \\>50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage.\n\nAdjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"70.3","spread":null},{"groupId":"OG002","value":"63.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"67.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis","description":"Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis","description":"Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"61.7","spread":null},{"groupId":"OG002","value":"50.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"3.7"},{"groupId":"OG001","value":"-21.8","spread":"2.6"},{"groupId":"OG002","value":"-15.5","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"3.4"},{"groupId":"OG001","value":"-16.5","spread":"2.4"},{"groupId":"OG002","value":"-5.7","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.9"},{"groupId":"OG001","value":"7.4","spread":"1.4"},{"groupId":"OG002","value":"7.7","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.9"},{"groupId":"OG001","value":"6.8","spread":"1.3"},{"groupId":"OG002","value":"8.6","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"3.8"},{"groupId":"OG001","value":"-10.6","spread":"2.7"},{"groupId":"OG002","value":"-9.2","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.9"},{"groupId":"OG001","value":"-11.3","spread":"2.7"},{"groupId":"OG002","value":"-3.0","spread":"3.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.5"},{"groupId":"OG001","value":"8.2","spread":"1.1"},{"groupId":"OG002","value":"10.0","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.5"},{"groupId":"OG001","value":"5.9","spread":"1.1"},{"groupId":"OG002","value":"7.6","spread":"1.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 32, 36, 48, 72, 96, 120, 144, 168 On-Treatment Analysis in Open Label Extension Treatment Phase","description":"Mean percent changes (and standard deviations) observed during the open-label extension period are provided.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.3","spread":"18.8"},{"groupId":"OG001","value":"-41.1","spread":"21.2"},{"groupId":"OG002","value":"-46.9","spread":"13.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.1","spread":"22.0"},{"groupId":"OG001","value":"-39.2","spread":"21.2"},{"groupId":"OG002","value":"-43.1","spread":"13.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.5","spread":"24.2"},{"groupId":"OG001","value":"-49.2","spread":"18.7"},{"groupId":"OG002","value":"-48.7","spread":"21.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.8","spread":"20.6"},{"groupId":"OG001","value":"-53.7","spread":"19.5"},{"groupId":"OG002","value":"-52.3","spread":"21.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.8","spread":"20.4"},{"groupId":"OG001","value":"-52.8","spread":"19.6"},{"groupId":"OG002","value":"-46.8","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.6","spread":"20.9"},{"groupId":"OG001","value":"-53.7","spread":"18.7"},{"groupId":"OG002","value":"-51.8","spread":"24.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.7","spread":"17.6"},{"groupId":"OG001","value":"-48.7","spread":"23.7"},{"groupId":"OG002","value":"-49.4","spread":"20.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.8","spread":"24.2"},{"groupId":"OG001","value":"-66.2","spread":"17.1"},{"groupId":"OG002","value":"-60.0","spread":"4.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":58},"commonTop":["Viral upper respiratory tract infection","Arthralgia","Headache","Upper respiratory tract infection","Fall"]}}}